Dr. Mary Disis
I've won the following awards
Scholarship, American Association of Medical Schools Women's Faculty Seminar
Award for Scientific Excellence, Cancer Treatment Research Foundation
Celebrating Hope Award of Scientific Achievement, Olympic Medical Center Foundation
Clinical Investigator Award, National Cancer Institute
Mid-Career Investigator Award in Patient Oriented Research, National Cancer Institute
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity.
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
Breast Cancer Research and Treatment
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature.
The Journal of Immunology
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Cancer Prev Res (Phila)., Aug;5(8):1036-43 (2012)
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Clin. Cancer Res., Jun;18(11):3122-31 (2012)
Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs.
ACS Nano., Mar;6(3):2591-601 (2012)
Defining the critical hurdles in cancer immunotherapy.
J Transl Med., 9(1):214 (2011)
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Clin. Cancer Res., Jan;18(2):499-509 (2012)
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
J Transl Med., 9:155 (2011)
TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
Clin. Cancer Res., Nov;17(21):6742-53 (2011)
Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.
OMICS., Sep;15(9):579-88 (2011)
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
Clin. Cancer Res., May;17(10):3064-76 (2011)
Wouldnâ€™t we all like to be a little more LEAN?
Clin Transl Sci., Oct;3(5):207-9 (2010)
ELISpot for measuring human immune responses to vaccines.
Expert Rev Vaccines., Mar;10(3):299-306 (2011)
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.
J. Clin. Oncol., Apr;29(12):1539-46 (2011)
TNM staging in colorectal cancer: T is for T cell and M is for memory.
J. Clin. Oncol., Feb;29(6):601-3 (2011)
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy.
Cancer Immunol. Immunother., Mar;60(3):433-42 (2011)
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.
J Transl Med., 8:130 (2010)